[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,74,107,150,180,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100590657","fmt-for-lung-and-associated-organ-rescue-efficacy-in-mdro-infected-ventilated-patients-100590657",false,"NCT06970262","FMT for Lung and Associated-organ Rescue Efficacy in MDRO-infected Ventilated Patients","FMT for Lung and Associated-organ Rescue Efficacy in Multidrug-resistant Organism (MDRO)-Infected Ventilated Patients: a Single-center, Open-Label, Randomized Controlled Trial","FLARE-MV","Inclusion Criteria:\n\n1. Age 18-70 years, inclusive, irrespective of sex or ethnic background;\n2. Admission to the intensive care unit (ICU) within 24-48 hours;\n3. Anticipated ICU length of stay of ≥7 days, as determined by the attending intensivist prior to enrollment;\n4. Mechanically ventilated patients with MDRO infection;\n5. Provision of written informed consent by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Severe systemic infection during early resuscitation, accompanied by hemodynamic instability, profound tissue hypoperfusion, or life-threatening electrolyte and acid-base disturbances;\n2. Clinician-assessed high risk of mortality within 5 days, or presence of formal treatment-limiting directives (e.g., do-not-intubate or do-not-resuscitate orders);\n3. Active gastrointestinal bleeding or perforation consistent with severe intestinal barrier dysfunction;\n4. Inability to tolerate enteral nutrition providing ≥50% of estimated caloric requirements due to structural intestinal pathology-including fibrotic bowel stenosis or high-output enterocutaneous fistula;\n5. Planned abdominal surgery or history of abdominal surgery within 14 days prior to enrollment;\n6. Confirmed diagnosis of fulminant colitis or toxic megacolon;\n7. Neutropenia defined as absolute neutrophil count \\\u003C 1.5 × 10⁹\u002FL;\n8. Recent exposure to high-risk immunosuppressive or cytotoxic agents within the preceding 3 months, including but not limited to: rituximab (within 6 months), anthracyclines (e.g., doxorubicin), or systemic corticosteroids at ≥20 mg\u002Fday prednisone-equivalent dose for ≥4 consecutive weeks;\n9. Pregnancy or lactation;\n10. Participation in another interventional clinical trial within 3 months prior to enrollment or ongoing at the time of study entry.","ALL","18 Years","70 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Multidrug-resistant organism (MDRO)-infection represents a substantial global health burden. In the intensive care unit (ICU), the concurrent administration of antibiotics, opioids, proton pump inhibitors (PPIs), vasoconstrictors, and parenteral nutrition-compounded by the intrinsic severity of critical illness-induces profound gut microbiota dysbiosis. Accumulating preclinical and clinical evidence indicates that such intestinal dysregulation may trigger distal immunomodulatory and microbial shifts in the lung via the gut-lung axis, thereby contributing to pulmonary microecological imbalance and impairing recovery trajectories. Although pulmonary microecology has garnered increasing scientific attention, the causal and temporal relationship between gut dysbiosis and the establishment or exacerbation of pulmonary microbial dysbiosis in MDRO-infecction remains inadequately characterized. As a result, it is currently unclear whether gut dysbiosis serves as a primary pathogenic driver, a disease-amplifying factor, or a secondary epiphenomenon in the context of MDRO-infecction-associated lung injury.\n\nFecal microbiota transplantation (FMT) is a targeted microbiome-modulating intervention that involves the transfer of functionally diverse, minimally processed microbial communities from comprehensively screened healthy donors to restore ecological stability and functional redundancy in the recipient gut. Robust clinical data demonstrate that FMT effectively decolonizes the gastrointestinal tract of MDROs and reduces the incidence of secondary infections in immunocompetent, non-critically ill populations. Over the past decade, FMT has demonstrated reproducible efficacy in recurrent Clostridioides difficile infection and emerging promise in select extra-intestinal inflammatory conditions-highlighting its capacity as a mechanism-informed strategy for systemic host-microbe recalibration. Given the established role of the gut as a reservoir for enteric pathogens implicated in sepsis, hospital-acquired bloodstream infections, and ventilator-associated pneumonia (VAP), we propose a prospective, single-center, open-Label, randomized controlled trial (RCT) enrolling mechanically ventilated adults with MDRO-infeccted ventilated patients. The primary objective is to evaluate whether adjunctive FMT-delivered via nasojejunal tube-decrease 28-day mortality.",[28,29,30],"Lung Infection","Microbial Colonization","Food Intolerance Syndromes","NOT_YET_RECRUITING","2026-04-28",{"date":34,"type":35},"2026-05-05","ACTUAL",{"date":37,"type":22},"2026-05-30",{"date":39,"type":22},"2027-12-31",{"name":41,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100303961","phase-3-clarithromycin-versus-azithromycin-in-the-treatment-of-mycobacterium-avium-complex-mac-lung-infections-100303961","NCT03236987","CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections","CLAZI","Inclusion Criteria:\n\n* patients 18 years of age or older\n* having a positive Mycobacterium avium complex sample showing the ATS \u002F IDSA infection criteria and requiring treatment\n* ATS \u002F IDSA infection criteria combine clinico-radiological criteria, associated with microbiological criteria\n* the exclusion of any other diagnosis on the thoracic CT, fibroscopy and bacteriological samples\n\nExclusion Criteria:\n\n* Known hypersensitivity to one of the study molecules (rifampicin, ethambutol, azithromycin, clarithromycin)\n* Relapse of an MAC infection,\n* Strain resistant to macrolides, based on genotyping susceptibility testing (genotyping susceptibility testing must be done before inclusion)\n* Treatment that interacts with cytochrome p450 that can not be replaced by another therapeutic,\n* HIV serology 1 and 2,\n* Renal insufficiency with creatinine clearance less than 30 ml \u002F min,\n* Pregnancy and breast feeding,\n* Contra-indication to one of the antibiotics,\n* Impossibility to follow the protocol due in particular to drug addiction according to the investigator,\n* Limited life expectancy, less than 6 months,\n* Patient already participating in a clinical trial on a medical treatment or a therapeutic strategy for non-tuberculous mycobacteria.",{"count":52,"type":22},424,[54],"PHASE3","MAC lung infections are a growing public health problem. The ATS \u002F IDSA 2007 guidelines for the treatment of these non-tuberculous mycobacterial infections recommend the use of a macrolide or azalide (clarithromycin or azithromycin), rifampicin or rifabutin and ethambutol.\n\nFor MAC disseminated infections, several studies have compared combinations containing clarithromycin or azithromycin and found no significant difference in efficacy. No randomized controlled trials have been performed for pulmonary infections to compare clarithromycin and azithromycin in terms of efficacy. Clarithromycin is often used as a first-line treatment in France, but its tolerance is often poor, particularly in terms of risk of hepatitis, metallic taste in the mouth, nausea or vomiting, and it interacts with many drugs via cytochrome p450 . In particular, it increases the toxicity of rifabutin, in particular in terms of uveitis. Azithromycin has fewer side effects especially less digestive toxicity and drug interactions than clarithromycin.\n\nThe hypothesis is therefore that the efficacy of azithromycin would be non-inferior in comparison with that of clarithromycin.",[28,57],"MAC Lung Disease",[59,60,61,62],"Clarithromycin","Azithromycin","Efficacy","Safety","RECRUITING","2025-11-17",{"date":66,"type":35},"2025-11-19",{"date":68,"type":35},"2018-02-05",{"date":70,"type":22},"2029-02-05",{"name":72,"class":42},"Centre Hospitalier Universitaire, Amiens",3,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":43},"100486919","unc-pleural-fluid-registry-100486919","NCT05620329","UNC Pleural Fluid Registry","University of North Carolina Pleural Fluid Registry","Inclusion Criteria:\n\n* Patients who are 18 years or older\n* Inpatients and outpatients\n* Diagnosed with pleural fluid, are referred for and undergo clinically indicated drainage who have clinical evidence of:\n* pulmonary infection (such as fever, leukocytosis, new or worsening infiltrate on chest x-ray, or clinical deterioration) with effusion\n* malignancy\n\nExclusion Criteria:\n\n* A subject will not be eligible for inclusion in this registry if, in the investigator's (or treating clinician's) opinion, the patient has any concurrent medical condition that may preclude their ability to undergo pleural fluid drainage safely.\n* Incarcerated individuals",{"count":82,"type":22},9999,"32 Years","OBSERVATIONAL","Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid registry for use in future studies.",[87,28,88,89,90],"Lung Cancer","Breast Cancer","Malignant Pleural Effusion","Empyema",[92,93,94,95,96,97],"biospecimen","pleural fluid","lung cancer","cancer","infection","breast cancer","2025-10-15",{"date":100,"type":35},"2025-10-16",{"date":102,"type":35},"2018-01-24",{"date":104,"type":22},"2050-01-24",{"name":106,"class":42},"UNC Lineberger Comprehensive Cancer Center",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":118,"conditions":119,"keywords":134,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":43},"100556693","identification-of-multiple-pulmonary-diseases-using-volatile-organic-compounds-biomarkers-in-human-exhaled-breath-100556693","NCT06528418","Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Inclusion Criteria:\n\n* Males or females, age must be 18 years old or above.\n* Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data.\n* Patients must have a clear clinical diagnosis.\n* All participants must sign a written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with a history of cancer other than lung disease.\n* Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants.\n* Individuals with other severe organic diseases or mental illnesses.\n* Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc.\n* Any other condition that researchers deem unsuitable for participation in this clinical trial.",true,"100 Years",{"count":117,"type":22},10000,"The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are:\n\n1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases.\n2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.",[87,28,120,121,122,123,124,125,126,127,128,129,130,131,132,133],"COPD","Bronchitis","Pulmonary Fibrosis","Pulmonary Embolism","Pulmonary Arterial Hypertension","Pulmonary Tuberculosis","Pulmonary Abscess","Emphysema","Lung Injury","Cystic Fibrosis of the Lung","Bronchial Asthma","Bronchiectasis","Interstitial Lung Disease","Preserved Ratio Impaired Spirometry",[135,136,137,138,139],"Pulmonary Disease","Volatile Organic Compounds","Human Exhaled Breath","micro Gas Chromatography-photoionisation","detector (μGC-PID) system","2025-03-23",{"date":142,"type":35},"2025-03-26",{"date":144,"type":35},"2024-06-30",{"date":146,"type":22},"2027-06-30",{"name":148,"class":149},"ChromX Health","INDUSTRY",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100514032","evaluation-of-virtual-reality-to-reduce-anxiety-pain-and-duration-of-non-emergency-vigile-bronchial-fibroscopy-avatar-100514032","NCT05973201","Evaluation of Virtual Reality to Reduce Anxiety, Pain and Duration of Non-emergency Vigile Bronchial Fibroscopy (AVATAR)","Evaluation De La Réalité Virtuelle Pour Réduire L'anxiété, La Douleur Et De La Durée D'une Fibroscopie Bronchique Vigile Non Urgente En Soins Critiques","AVATAR","Inclusion Criteria:\n\n* Adults (over 18 years of age)\n* Hospitalized in a critical care unit (intensive care and intensive care)\n* Conscious (Glasgow score \\>13)\n* Spontaneous ventilation\n* Requiring the realization of a FB\n* First BF during hospitalization\n* Having signed a consent to participate in the study\n* Affiliation to social security\n\nExclusion Criteria:\n\n* Non-French-speaking patient\n* Protected minors or adults who cannot consent to participate\n* People with major neurocognitive impairment\n* Patient refusing to participate in the study\n* Patient on State medical aid\n* Patient under guardianship or curatorship or under judicial protection\n* BF for a vital emergency\n* Prior inclusion in the study\n* Pregnant or breastfeeding women\n* Presence of a tracheostomy or tracheostomy\n* Participation in other intervention research\n* Epilepsy\n* Visual impairment (blindness) or severe hearing impairment (hearing loss, deafness) that does not allow the use of the helmet\n* Psychiatric pathologies such as delusional disorders, hallucinations or schizophrenia.\n* Autism spectrum disorders\n* Patient sensitive to motion sickness\n* Refractory migraine under treatment",{"count":159,"type":22},120,[25],"Bronchial fibroscopy (BF) is a routine practice examination in critical care areas. It can be useful either for the diagnosis of the causal pathology of respiratory distress or for the diagnosis of lung infection, sometimes nosocomial. In patients in spontaneous and conscious ventilation, BF are performed vigil after local anesthesia according to the recommendations of the Société de Pneumologie de langue Française. The good tolerance of the examination and its good conduct may require the use of anxiolytics, sedatives or analgesics to limit the traumatic experience of a highly anxiety-provoking examination. Virtual reality (VR) combines a set of paramedical techniques (hypnosis, music therapy, sophrology) and is now a non-drug alternative to improve the tolerance of certain invasive gestures.VR has been shown to reduce pain and anxiety during first pathways placement or digestive endoscopies. To date, there is no evidence of the benefit of VR when performing semi-urgent BF in critical care areas.",[163,28],"Respiratory Disorder",[165,166,167,168,169],"Virtual reality","Pulmonary fibroscopy","Anxiety","Pain","Intensive care","2024-11-29",{"date":172,"type":35},"2024-12-04",{"date":174,"type":35},"2023-10-19",{"date":176,"type":22},"2025-10-26",{"name":178,"class":42},"Assistance Publique - Hôpitaux de Paris",5,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":187,"targetDuration":189,"studyType":84,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":43},"100565910","radiolabelled-nectin-4-targeted-lmw-probe-petct-in-patients-with-lung-lesions-100565910","NCT06648317","Radiolabelled Nectin-4 Targeted LMW Probe PET\u002FCT in Patients With Lung Lesions","Inclusion Criteria:\n\n1. 18-75 years old, male or female;\n2. Heart function is normal;\n3. Normal heart function;\n4. Estimated survival ≥12 weeks;\n5. Good follow-up compliance;\n6. presence of at least one measurable target lesion according to RECIST1.1 criteria;\n7. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test;\n8. Patients recommended by clinicians to undergo PET\u002FCT examination for tumor diagnostic staging;\n9. The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.\n\nExclusion Criteria:\n\n1. Serious abnormality of liver, kidney and blood;\n2. Pregnant patients;\n3. Pregnant and lactation women;\n\n3\\) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.","75 Years",{"count":188,"type":22},20,"2 Years","To evaluate the ability of \\[68Ga\\]N188 to detect nectin-4 overexpression in patients with lung lesions.",[192,28],"Lung Cancer, Non-Small Cell","2024-11-20",{"date":195,"type":35},"2024-11-25",{"date":197,"type":35},"2024-11-21",{"date":199,"type":22},"2025-12-01",{"name":201,"class":42},"Peking University Cancer Hospital & Institute",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":43},"100487696","effects-of-prone-position-after-major-abdominal-surgery-100487696","NCT05630443","Effects of Prone Position After Major Abdominal Surgery","EPOS","Patients eligable for abdominal surgery aim to cure with:\n\nInclusion Criteria:\n\n\\- malignancy of the esophagus, gastric- or pancreas\n\nExclusion Criteria:\n\n-.not able to understand Swedish in writing or speaking\n\n\\- preoperatively unable to perform a prone position",{"count":210,"type":22},200,[25],"Evaluation of postoperative prone position after major abdominal surgery. A randomized clinical trial of 100+100 patients and further add a voice\u002Fspeech\u002Fsinging protocol.",[214,215,28],"Surgery","Complications, Postoperative",[217,218,219,220],"complications postoperative","lungcomplications","abdominal surgery","prone position","2024-05-29",{"date":223,"type":35},"2024-05-30",{"date":225,"type":35},"2022-10-01",{"date":227,"type":22},"2026-12-31",{"name":229,"class":230},"Vastra Gotaland Region","OTHER_GOV"]